Periodontal Therapeutics Market is Projected to Soar at a Value CAGR of 9.0% from 2018 to 2026

Transparency Market Research (TMR) has published a new report titled, “Periodontal Therapeutics Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”. According to the report, the global periodontal therapeutics market was valued at US$ 500 Mn in 2017 and is projected to expand at a CAGR of 9.0% from 2018 to 2026. The report suggests that increase in incidence of periodontal diseases is expected to drive demand for therapeutics used in the treatment of these diseases from 2018 to 2026.

Rise in measures adopted by local governments in North America to improve oral care among individuals, especially those suffering from untreated dental diseases, is likely to help the region sustain its share of the global periodontal therapeutics market. Substantial rise in the geriatric population and increase in awareness among consumers about dental health are anticipated to boost demand for periodontal therapeutics in the region.

Rise in focus of major players to increase market share through inorganic growth strategies and increase in burden of periodontal diseases across the globe are anticipated to drive the market during the forecast period. Surge in expenditure on oral health care services, especially in developed countries, is anticipated to boost demand for products used in the treatment of periodontal diseases. Additionally, increase in awareness about the benefits associated with the use of local antibiotics such as targeted drug delivery and controlled release of drug is expected to fuel the growth of the market from 2018 to 2026. However, side effects associated with the use of antibiotics and uninsured dental care in several developed and developing countries is likely to restrain the market.

Request A Sample Copy @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=24614

The report offers detailed segmentation of the global periodontal therapeutics market based on product type and distribution channel. In terms of product type, the local antibiotics segment is anticipated to account for significant share of the market from 2018 to 2026. Growth of the segment is attributed to advantages offered by locally applied antibiotics such as reduction in the potential problems associated with the use of systemic antibiotic drugs and controlled release of the drug. The systemic antibiotics segment is likely to account for market share of 30.0% by 2026 due to continued preference for systemic antibiotics such as amoxicillin, azithromycin, and metronidazole among dental practitioners in low income countries.

Hospital Pharmacies to Account for Major Share

The hospital pharmacies segment is expected to account for the leading share of the market by 2026. The segment is also likely to post the strongest growth rate during the forecast period. Drug stores accounted for over 12% market share in 2017. The segment is expected to lose market share during the forecast period owing to rise in the number of hospital pharmacies and retail pharmacies globally.

Asia Pacific to Post Strong Growth Rate

North America held the largest share of the global periodontal therapeutics market in 2017. High market share of the region is due to increase in measures to improve dental hygiene among the general population and development of novel therapeutics used in the treatment of periodontal diseases by major players. Countries in Asia Pacific are expected to witness increase in the population with periodontal diseases and exponential rise in the geriatric population. This is likely to drive the market in the region during the forecast period. Surge in expenditure on oral health care by individuals in countries in Europe is likely to propel the periodontal therapeutics market during the forecast period.

Key Players such as Den-Mat Holdings LLC, Valeant Pharmaceuticals International, Inc., and Dexcel Pharma to Lead the Market

The report also provides profiles of leading players operating in the global periodontal therapeutics market. These include Den-Mat Holdings LLC, Dexcel Pharma, Valeant Pharmaceuticals International, Inc., 3M Company, Oral Science, and Kaken Pharmaceutical Co., Ltd.

Parkinson’s Disease Therapeutics Market to Attain a Value of US$ 5.24 Bn by 2025

The global Parkinson’s disease therapeutics market was valued at US$ 2.18 Bn in 2016 and is projected to register a cumulative annual growth rate (CAGR) of more than 10.9% from 2017 to 2025, according to a new report titled “Parkinson’s Disease Threapeutics Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017–2025” published by Transparency Market Research (TMR) (. The report states that high prevalence of Parkinson’s disease, rise in geriatric population across the globe, increase in funding for clinical research and grants, etc. are expected to spur the growth of the Parkinson’s disease therapeutic drugs during the forecast period, i.e. 2017 to 2025. North America and Europe are projected to dominate the global Parkinson’s disease therapeutics market in the near future, primarily due to the large base of aging population, high clinical R&D budget to address the unmet needs of Parkinson’s disease, and increase in awareness regarding the disease in these regions. Europe is estimated to dominate the global Parkinson’s disease therapeutics market by the end of 2025, which can be ascribed to the high prevalence and rise in incidence rate of Parkinson’s disease in the developed countries in the region such as Germany, France, the U.K., and Italy, promising product pipeline, and various initiatives undertaken by the government and non-profit organizations to promote awareness regarding the disease. The Parkinson’s disease therapeutics market in Europe is expected to witness the highest CAGR of more than 11.0% from 2017-2025.

Request A Sample Copy @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=26975

High prevalence and rise in incidence rate of Parkinson’s disease to fuel the global market

Parkinson’s disease is a highly prevalent age-related neurodegenerative disorder, affecting millions of people worldwide and causing severe impact on their physical, psychological, as well as emotional health. The exact cause of Parkinson’s disease is not known. It is largely prevalent among the geriatric population. Classifying by gender, men are one-and-half times more affected by the disease than women. According to the Parkinson’s Foundation based in the U.S., it is estimated that worldwide around 7 to 10 million people are affected by Parkinson’s disease and around 1 million Americans are living with it. However, the exact number of patients suffering from Parkinson’s disease is known due to incompleteness and inconsistency in the prevalent studies and underdiagnosed cases. According to the Global Burden of Disease Study, it is estimated that around 13 million people will be affected by Parkinson’s disease worldwide by the year 2040. China has the world’s largest population affected with Parkinson’s disease, which is an estimated 2.5 million people, and the number is likely to become double by the end of 2030, accounting for half of the world’s population suffering from the disease. The rapidly growing geriatric population, coupled with high prevalence and increasing incidence rate of Parkinson’s disease in the developed countries, is projected to a key driving factor of the Parkinson’s disease therapeutics market during the forecast period.

Levodopa combination drugs to be an attractive product segment

The report offers detailed segmentation of the global Parkinson’s disease therapeutics market based on drug class, route of administration, and distribution channel. Among drug classes, the levodopa combination drugs segment is poised to account for the leading share of the global market during the forecast period from 2017 to 2025. Levodopa combination therapy is considered a highly-effective treatment for the motor symptoms associated with Parkinson’s disease and is commonly recommended by physicians across the globe. Carbidopa and levodopa combination therapy is commonly used for management of motor fluctuations in Parkinson’s disease. The recent approval by the United States FDA and launch of Duopa in 2015 by AbbVie Inc. had significantly promoted levodopa combination drugs in 2016. Also, the anticipated launch of pipeline study of CVT-301 by Acorda Therapeutics, Inc. and ND0612 from Mitsubishi Tanabe by the end of 2019 is estimated to propel the segment’s growth during the forecast period

Oral route of administration, followed by intestinal infusion segment, dominates the market

In terms of route of administration, the oral route is projected to dominate the global Parkinson’s disease therapeutics market during the forecast period and is estimated to expand at a CAGR of more than 7.5% from 2017-2025. More than 70% of the drugs available for treatment of Parkinson’s disease are in the tablet and capsule form. Some of the drugs are orally disintegrated. However, the estimated launch of sublingual film by SUNOVION and inhaled formulation by Acorda Therapeutics, Inc. during the forecast period is likely to gain market exceeding 15% by the end of 2025. Also, rise in adoption and demand for subcutaneous injections and promising pipeline products with subcutaneous route of administration for home management of Parkinson’s disease are estimated to limit the growth of the oral route of administration segment by the end of 2025.

Retail pharmacy, followed by hospital pharmacy segment, dominates the market

Among distribution channels, the retail pharmacy segment is projected to hold the dominant share of the global Parkinson’s disease therapeutics market during the forecast period and is likely to expand at CAGR of more than 11% from 2017 to 2025. Easy availability of Parkinson’s therapeutic drugs at retail pharmacies, low price of the drugs, and expansion of leading retail pharmaceutical chains across the globe are driving the growth of the segment. The hospital pharmacy segment is the second leading shareholder of the global Parkinson’s disease therapeutics market. However, the segment is likely to lose its market share by the end of 2025. Intestinal infusion drugs and subcutaneously administered drugs, and certain patented drugs, to an extent, have contributed to the key market share of the hospital pharmacy segment in 2016. The online pharmacy segment is poised to grow at as significant CAGR of more than 12% during the forecast period.

Huge incremental opportunity in Europe

In terms of value, Europe dominated the global Parkinson’s disease therapeutics market in 2016. The region is estimated to gain market share by the end of 2025. The dominance of Europe can be primarily attributed to the high prevalence of Parkinson’s disease in the region, availability of and high adoption of levodopa combination drugs, and high clinical R&D budget to address the unmet needs in Parkinson’s disease. According to the European Parkinson’s Disease Association, around 1.2 million people in European Union are affected with Parkinson’s disease. In Germany, around 260,000 people; in Italy, 150,000 people; and in the U.K., around 120,000 people are affected by the disease. The highest incidence rate of Parkinson’s disease is observed in France with around 36-49 cases per 100,000 people. The Parkinson’s disease therapeutics market in Europe is estimated to grow at the highest CAGR of more than 11% during the forecast period. North America is the second leading market for Parkinson’s disease therapeutics. Rapid growth in the aging population of the U.S., rise in awareness regarding Parkinson’s disease, and new product approvals and launches in the region have contributed to the dominant share of the region. Moreover, high clinical R&D budget by the governments, private players, and non-profit organizations are estimated to fuel the expansion of the Parkinson’s disease therapeutics market in North America during the forecast period. The Parkinson’s disease therapeutics market in Asia Pacific is poised to grow at a moderate rate during the forecast period.

Key trend of new product development and launch in the international market is observed among leading players

The report also provides profiles of the leading players operating in the global Parkinson’s disease therapeutics market. AbbVie Inc., Novartis AG, F. Hoffmann-La Roche AG, Teva Pharmaceutical Industries Ltd., and UCB Inc. are some of the prominent players in the market having proprietary products and technologies. Most of them are focused on new product development, approvals, and commercialization of novel drugs to gain the first-mover’s advantage and address the unmet needs in the Parkinson’s disease therapeutics market. For instance, In January 2015, AbbVie’s flagship product, DUOPA (Combination Drug of carbidopa and levodopa), received the approval of the United States FDA for the treatment of advanced Parkinson’s disease. Duopa is administered through a unique technology directly into the intestine of the patient through the stoma. It is the first and only kind of product administered through intestinal infusion. In 2016, the ACADIA Pharmaceuticals Inc. launched its antipsychotic drug, Nuplazid, in the U.S. Nuplazid is the first and only drug approved by the United States FDA for the management of hallucination and delusion associated with Parkinson’s disease. Other prominent players operating in the global Parkinson’s disease therapeutics market include STADA Arzneimittel AG, GlaxoSmithKline plc, Valeant Pharmaceuticals International, Inc., Merck & Co., Inc., and Impax Laboratories Inc.

Drug Delivery Systems Market is Projected to Soar at a Value CAGR of 6.9% from 2017 to 2025

Transparency Market Research (TMR) has published a new report titled “Drug Delivery System Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017–2025”. According to the, the global drug delivery system market was valued at approximately US$ 510.0 Bn in 2016 is projected to expand at CAGR of over 6.9% from 2017 to 2025. The report suggests that rise in prevalence of diseases and increases in demand for self-administration devices are likely to spur demand for drug delivery system in the during the forecast period (2017 to 2025). Key players introduce new drugs delivery systems and devices in developed markets such a North America and Western Europe. Hence, these regions are likely to account for dominant share of the global drug delivery system market. Rise in R&D investment and launch of new and advanced technologies in emerging markets such as Japan and India are expected to boost the drug delivery system market in Asia Pacific. The market in the region is expected to expand at a CAGR of around 7.6% from 2017 to 2025.

Targeted Drug Delivery System Dominates the Market Followed by Polymeric Drug Delivery

The report offers detailed segmentation of the global drug delivery system market based on delivery system, application, route of administration, and geography. In terms of delivery system, the targeted drug delivery segment is expected to account for a dominant share of the global market during the forecast period. Simplified drug administration protocols, avoidance of first pass metabolism, lower dose required as compared to the conventional drug delivery, and higher therapeutic effect in small doses are some factors propelling the segment. The polymeric drug delivery segment is likely to expand at a considerable growth rate during the forecast period. Polymeric drug delivery systems allow localized drug delivery in large quantity for the treatment of chronic diseases such as cancer (more specifically, solid tumors) with lower toxicity. This is a major factor driving the segment.

Request A Sample Copy @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=41543

Oncology and CNS: Top Two Application Areas of the Drug Delivery System Market

Based on application, the oncology segment is projected to hold a dominant share of the global drug delivery system market during the forecast period. It is likely to expand at CAGR of more than 7.4% from 2017 to 2025. Dominance of this segment is attributed to continuous innovations in drug offerings and wide product portfolio of major and local manufacturers. For instance, in September, 2017, Amgen Inc. and ALLERGAN collectively obtained FDA approval for the use of MVASI to treat five types of cancer, which includes metastatic carcinoma of the cervix, metastatic renal cell carcinoma, glioblastoma, metastatic colorectal cancer (mCRC), and non-squamous non-small cell lung cancer (NSCLC). Continuous launch of new products and increase in the number of patients in developed and developing countries are likely to drive the segment between 2017 and 2025. According to WHO report, in 2015, around 8.8 million people died of cancer, of which, around 1.69 million died of lung cancer and 788,000 succumbed to liver cancer. This highlights the significant need for advanced drug delivery system to treat cancer. CAN and diabetes segment, accounted for more than 36.0% share of global drug delivery system market in 2016, in terms of value. It is anticipated to have substantial growth and account for approximately 36% of market share by 2025.

Asia Pacific to Expand at an Exponential Growth Rate and Offer Significant Incremental Opportunity

In terms of value, North America was leading contributor to the global drug delivery system market in 2016. North America accounted for a key share of the market due to rise in prevalence of acute and chronic diseases in the U.S. According to WHO report 2016, non-communicable diseases accounted for 23% of total deaths in the U.S. Moreover, availability of advanced technology and facilities in the health care system also drive the drug delivery system market in the U.S. Moreover, rise in research & development spending in emerging markets such as Singapore and Japan is fueling the market in Asia Pacific. Economic growth in countries such as Brazil is increasing health care expenditure through the rise in private health insurance and entry of international drug manufacturers and health care providers in Latin America. Hence, the market in the region is likely to expand at a CAGR of 5.5% from 2017 to 2025.

Key Players such as Boston Scientific Corporation, Johnson & Johnson Services, Inc. and Pfizer, Inc. are Likely to Continue to Lead the Global Drug Delivery System Market

The report also provides profiles of leading players operating in the global drug delivery system market, which include AstraZeneca plc., Pfizer Inc., Novartis AG, Bayer AG, F. Hoffmann-La Roche Ltd, Johnson & Johnson, Amgen Inc., Becton, Dickinson and Company, and Baxter International Inc. These player engage in expansion of drugs delivery system portfolio by improving existing drug delivery devices and developing and launching of new drug delivery system through collaboration. For instance, Becton, Dickinson and Company developed and launched 6mm pen needle for insulin to treat diabetes.

Drug and Gene Delivery Systems Market to Attain a Value of US$ 917 Bn by 2025

Drug and Gene Delivery Systems Market: Overview

Drug delivery includes formulations, technologies, methods, and systems used for transferring an active pharmaceutical ingredient into the body as desired, in order to safely accomplish its therapeutic effect. Gene delivery is a procedure employed to introduce foreign DNA into host cells. Rising prevalence of chronic diseases such as cancer and diabetes is increasing the demand for drug and gene delivery systems. According to JAMA Oncology, around 17.5 million new cancer cases were reported across the world in 2015. According to a WHO report published in 2017, around 1.0 million people died of HIV infection across the globe in 2016. Several advancements have been made in the field of drug and gene delivery systems such as nanoparticle technology, Prodrug formulation, liposomes & hydrogels, particle engineering & particulate systems, and three-dimensional printing (3DP) in order to attain sustained and controlled release of drugs.

Report Overview @ https://www.transparencymarketresearch.com/drug-gene-delivery-system-market.html

Drug and Gene Delivery Systems Market: Segmentation

The drug and gene delivery systems market has been segmented in terms of delivery system, route of administration, application, and geography. Based on delivery system, the market has been segmented into drug delivery systems and gene delivery systems. The drug delivery systems segment has been sub-segmented into intrauterine implants, Prodrug implants, polymeric drug delivery, and targeted drug delivery. The gene delivery systems segment has been sub-segmented into viral gene delivery, non-viral gene delivery, and combined hybrid system. The viral gene delivery sub-segment has been further classified into adenovirus vector, lentivirus vector, retrovirus vector, adeno-associated virus vector, Sendai virus vector, herpes simplex virus vector, and others. The non-viral gene delivery sub-segment has been further classified into natural organic compounds, physical methods, and chemical methods. Based on route of administration, the market has been segmented into oral, injectable, inhalation, transdermal, ocular, nasal, and topical. In terms of application, the market has been divided into infectious diseases, oncology, ophthalmology, urology, diabetes, CNS, and others. Based on geography, the market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Request A Sample Copy @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=26135

The research is a combination of primary and secondary research, which has been conducted for understanding and arriving at trends and used to forecast the revenue expected to be generated in the global drug and gene delivery systems market in the near future. Primary research represents a bulk of our research efforts with information collected from in-depth interviews and discussions with a number of key market experts and opinion leaders. Secondary research involved study of company websites, annual reports, press releases, investor presentations, analyst presentations, and various international and national databases. The report provides estimated market size (in US$ Bn) of segments based on delivery system, route of administration, application, and geography for the period from 2015 to 2025, considering the macro and micro environmental factors. The revenue generated by each of these segments was calculated by considering the drug and gene delivery system market product sales.

The report comprises an elaborate executive summary which includes market snapshot that provides information about various segments of the market. It also provides information and data analysis of the market with respect to segments based on delivery system, route of route of administration, application, and geography. The market overview section of the report analyzes market dynamics such as drivers, restraints, and opportunities that influence the drug and gene delivery systems market. The report also provides Porter’s five forces analysis, the acquisitions timeline of drug and gene delivery systems market companies, SWOT analysis of the market, regulatory scenario, and comparative analysis of the drug and gene delivery systems market policies.

Market share analysis among the market players is analyzed to signify the contribution of these players in the market in terms of percentage share. All these factors would help market players decide about their business strategies and plans in order to strengthen their position in the global market. Based on geography, the market has been categorized into regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The study also covers detailed country analysis contributing majorly in the drug and gene delivery systems market.

The report also profiles major players operating in the drug and gene delivery systems market and provides various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Companies profiled in the report are Oxford BioMedica, Pfizer, Inc., Amgen Inc., Astrazeneca plc, Bayer AG, SiBiono GeneTech Co., Shanghai Sunway Biotech Co., Ltd., Human Stem Cells Institute, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Novartis AG, and Becton, Dickinson and Company.

Antacids Market is Anticipated to Reach a Value of US$ 18.7 Bn by 2025

Global Antacids Market: Snapshot

The global antacids market has been displaying steady growth, and going forward it is likely to remain this way. The growth of the antacids market is primarily driven by changing dietary habits and growing geriatric population worldwide. The intake of medication for health conditions and increasing incidence of gastro esophageal reflux diseases generally among geriatrics is driving the demand for antacids among this population. For instance, the highest proportion of geriatrics in Japan in 2014, as per statistics of the World Bank is acting in favor of the Asia Pacific antacids market.

The trend of self-medication for occasional heartburn and acidity and the easy availability of antacids over the counter is also driving the sales of antacids.

Providing headwinds to the market is serious side effects associated with the prolonged use of antacids such as proton pump inhibitors and H2 antagonists and the rising popularity of generic drugs in underdeveloped and developing countries.

Request A Sample Copy @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=32864

A report by Transparency Market Research (TMR), estimates the global antacids market will clock a 3.7% CAGR between 2017 and 2025, for the market to become worth US$18.7 bn by the end of 2025.

Proton Pump Inhibitors Drug Class Segment to continue to hold Leading Revenue Share

The global antacids market could be segregated according to drug class, formulation type, distribution channel, and region. The leading segment for each category that could create ample opportunities for market players are studied as well in this report. On the basis of drug class, the market could be classified into proton pump inhibitors, H2 antagonist, and acid neutralizers. Amongst all, proton pump inhibitors led the market in 2016 and the trend is anticipated to continue over the forecast period. This is mainly because of their efficacy and easy availability as prescription and over the counter drugs as affordable price. However, acid neutralizers are expected to emerge as a significant segment on the back of their extensive use for occasional heartburn and acidity and due to their availability in a range of formulations and flavors.

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=32864

Depending upon formulation type, the global antacids market could be classified into tablet, liquid, powder, and others. Tablet was the leading segment in 2016 and is anticipated to hold on to its dominant position over the forecast period. Safety, convenience in administration and storage, and low cost factor are the chief factors aiding the growth of tablet segment of the market. The others segment, on the other hand, that comprises products such as melt in mouth micro granules and thin films is anticipated to display a robust CAGR over the forecast period.

On the basis of distribution channel, the segments into which the global antacids market is divided are hospital pharmacies, retail pharmacies, and others. Of them, the others segment which include online pharmacy and drug store led the market in 2016. Rising adoption of e-commerce and increasing number of online medicine providers are fuelling this segment’s expansion.

APEJ to Emerge Significant with Overpowering CAGR

The global antacids market has been classified geographically into five key regions, namely North America, Asia Pacific, Latin America, Europe, and the Middle East and Africa. Europe held the leading share of the overall market in 2016 due to factors such as increasing incidence of gastro esophageal reflux diseases and growing geriatric population. The region being home to some of the key players is also stoking growth of this regional market.

Asia Pacific stood as the second-leading market for antacids in 2016. The region is predicted to clock a robust 4.5% CAGR between 2017 and 2025 to account for the second-leading revenue through this period. China and India are key domestic markets in the region due to improvement of healthcare services.

Leading players in the global antacids market profiled in this report include AstraZeneca, Bayer AG, Boehringer Ingelheim GmbH, Dr. Reddy’s Laboratories Ltd., GlaxoSmithKline plc, Johnson & Johnson, Pfizer Inc., Procter & Gamble, Reckitt Benckiser Group plc, Sanofi, Sun Pharmaceuticals Ltd., Takeda Pharmaceutical Company Ltd., and Valeant Pharmaceuticals among others.

X-Ray Photoelectron Spectroscopy Market is Expected To Demonstrate a CAGR of 5.8% from 2015 to 2023

The X-ray photoelectron spectroscopy (XPS) market is characterized by the presence of large regional players, particularly in several developed nations. Prominent players operating in the market include Thermo Fisher Scientific, ULVAC-PHI, Japan Electron Optics (JEOL) Ltd., Evans Analytical Group LLC., and Kratos Analytical Ltd. Leading companies are consolidating their presence in various emerging markets such as China, India, and Australian, notes Transparency Market Research (TMR). Top players are actively capitalizing on numerous opportunities opening up there, in a move to strengthen their shares.

The global X-ray photoelectron spectroscopy market stood at US$443.5 million in 2014 and is expected to reach US$749.8 million by the end of 2023. The market is anticipated to rise at 5.8% CAGR from 2015 to 2023.

Request A Sample Copy @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=9194

Elemental Analysis Gaining Prominence in Understanding Industrial Processes

Regionally, the X-ray photoelectron spectroscopy market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. Of these, Asia Pacific is anticipated to rise at the leading CAGR during the forecast period. The regional market is expected to be driven by constant advancements in surface characterization methods and substantial improvements in infrastructure in developing nations.

Based on the type of analysis done with XPS, the market is segmented into elemental analysis forensic analysis, contamination analysis, and electronic density estimation. Among these, the elemental analysis is projected to rise at the leading CAGR over the forecast period. The dominance of the segment is attributed to the demand for XPS for analyzing the chemical state and electronic state various the elements.

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=9194

Pharmaceutical and Medical Sectors to Witness Extensive Demand

The X-ray photoelectron spectroscopy market is primarily driven by the growing demand for technologies for analyzing the surface chemistry of materials in a number of industries including healthcare, pharmaceuticals, automotive, aerospace, semiconductors, and electronics. XPS is being increasingly used in surface characterization in order to alter or modify the properties of materials such as corrosion rates, catalytic activities, adhesive properties, and wettability. This is gaining prominence in improving the efficacy of surface engineering in these industries.

The burgeoning application of XPS technology in material researches in the medical and pharmaceutical industries is propelled by their substantial role in drug safety determination processes. The increasing application of XPS in understanding the spatial control of a variety of biomolecules and cells used in tissue engineering research is anticipated to boost the market. Furthermore, stringent regulations related to the testing of the effectiveness of the molecules used in drug discovery activities have accentuated the X-ray photoelectron spectroscopy market. The application of XPS as surface characterization tools in the healthcare industry is gaining traction in the healthcare industry, thereby catalyzing the market growth.

However, the lack of alternative spectroscopic methods and the paucity of expertise in using XPS techniques are crucial factors likely to impede the market to an extent. Nevertheless, the growing popularity of X-ray photoelectron spectroscopy methods in forensic analysis is expected to create a plethora of exciting opportunities for several market players. Furthermore, recent advancements in surface engineering technologies have improved the efficacy of the XPS techniques leading to the advent of methods with rapid turnaround times. The demand for novel forensic tools is anticipated to open up lucrative growth avenues in the coming years.

Menopausal Hot Flashes Market Opportunity will Rise to US$ 5,284.1 Mn by 2023

The global menopausal hot flashes market is fragmented moderately. The top eight players in the market collectively held a share of more than 50% in 2014. Novartis AG and Pfizer Inc., are the top two players within the market, accounting for nearly 30% of the market in 2014, states a new research study by Transparency Market Research (TMR). Pfizer is likely to benefit from its well established presence across North America whereas Novartis is gaining on account of its efforts directed towards expanding its product portfolio for the treatment of menopausal hot flashes.

According to the report by TMR, the global menopausal hot flashes market will be worth US$5.28 bn by the end of the forecast period. On the basis of therapy, the demand for non-hormonal therapies for menopausal hot flashes is increasing. On the basis of geography, North America is leading on account of the rising incidence of menopausal vasomotor symptoms. Asia Pacific is anticipated to one of the most lucrative regional markets on account of the rising awareness among the population regarding menopause-related health issues.

Request A Sample Copy @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2856

Initiatives taken by Governments to Increase Awareness Level Driving Demand

According to a TMR analyst, “the increasing incidences of women suffering from hot flashes, night sweats on account of menopause is a key factor boosting the growth of this market.” Governments across the globe are taking several initiatives to create awareness among women regarding women’s health after menopause. There are several private healthcare institutes which are also focusing on creating awareness and providing effective care and treatment for menopausal hot flashes.

Speedy Approval of New Drugs Boosting Growth of Market

A key factor boding well for the market is the speedy approval of several new drugs or therapeutics for menopausal hot flashes. This is also working well for market players as its is helping create new avenues of growth. The market is also benefitting from the rise in the number of working women and the growing importance of career for women, leading to a higher ability to spend on treatment and rise in demand for several hygiene products and treatment solutions for menopausal symptoms so as to be able to carry out their professional duties and responsibilities. As an increasing number of women worldwide are realizing that getting effective menopausal treatment boosts good health, self-confidence, self-esteem, and overall quality of life, the demand for these drugs will soar high.

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2856

Patent Expirations of Key Drugs to Affect Market

On the other hand, home remedies are being adopted by many women in underdeveloped nations, which is restricting the growth of the global menopausal hot flashes market. Also, the availability of cheaper alternative therapies is also affecting market’s growth. The market will also be affected by the patent expirations of popular menopausal hot flashes drugs. This is anticipated to strike a blow to some of the most popular market players. Also, the emergence of cheaper generic drugs will impact the menopausal hot flashes market negatively.